What does DR. KAAT GULDOLF - NEUROLOGIE do?

DR. KAAT GULDOLF - NEUROLOGIE is a specialist medical practice in Stekene. Private Limited, started on 1 October 2020, 1 establishment.

What is the address of DR. KAAT GULDOLF - NEUROLOGIE?

The registered office of DR. KAAT GULDOLF - NEUROLOGIE is located at Kemelstraat(STE) 30A, 9190 Stekene.

Is DR. KAAT GULDOLF - NEUROLOGIE still active?

Yes. According to the CBE (30 September 2026) DR. KAAT GULDOLF - NEUROLOGIE is active, legal situation “Normale toestand”, started on 1 October 2020.

Is DR. KAAT GULDOLF - NEUROLOGIE registered on Peppol?

Yes, DR. KAAT GULDOLF - NEUROLOGIE is registered on the Peppol network with ID 0208:0755535077.

What is the enterprise number of DR. KAAT GULDOLF - NEUROLOGIE?

The enterprise number of DR. KAAT GULDOLF - NEUROLOGIE is BE0755535077.

When was DR. KAAT GULDOLF - NEUROLOGIE founded?

DR. KAAT GULDOLF - NEUROLOGIE was founded on 1 October 2020.

Who are the directors of DR. KAAT GULDOLF - NEUROLOGIE?

According to the 2025 annual accounts, the directors of DR. KAAT GULDOLF - NEUROLOGIE are: Kaat Guldolf.

Is DR. KAAT GULDOLF - NEUROLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 1 October 2020; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. KAAT GULDOLF - NEUROLOGIE make in 2025?

DR. KAAT GULDOLF - NEUROLOGIE posted a profit after taxes of € 81,951 in financial year 2025.

What is the revenue of DR. KAAT GULDOLF - NEUROLOGIE?

As a small company, DR. KAAT GULDOLF - NEUROLOGIE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 106,261.

DR. KAAT GULDOLF - NEUROLOGIE (Private Limited) - Stekene

Dossier DR. KAAT GULDOLF - NEUROLOGIE, printed on 30 September 2026 from databakkes.be/en/0755535077/dr-kaat-guldolf-neurologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. KAAT GULDOLF - NEUROLOGIE from Stekene, company number BE0755535077, closed financial year 2025 with a result of € 81,951 after tax. For that financial year DR. KAAT GULDOLF - NEUROLOGIE recorded a gross margin of € 106,261 and equity of € 165,075. Compared with financial year 2024, the result moved from € 77,875 to € 81,951. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on January 5, 2026.

What it is worth Healthy

€ 165,075

▼ 38% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 81,951

▲ 5% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 183,301

▼ 35% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 182,743 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 1,051

▲ 70% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 4,830

▲ 152% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,253

▼ 69% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 212,543 Gross margin 2022: € 212,543 First fiscal year in the series	€ 40,943 Gross margin 2023: € 40,943 ▼ 81% vs 2022 (€ 212,543) Unfavourable step	€ 110,086 Gross margin 2024: € 110,086 ▲ 169% vs 2023 (€ 40,943) Favourable step	€ 106,261 Gross margin 2025: € 106,261 ▼ 3% vs 2024 (€ 110,086) Unfavourable step	▼ 3%
Profit after taxes	€ 159,214 Profit after taxes 2022: € 159,214 First fiscal year in the series	€ 28,411 Profit after taxes 2023: € 28,411 ▼ 82% vs 2022 (€ 159,214) Unfavourable step	€ 77,875 Profit after taxes 2024: € 77,875 ▲ 174% vs 2023 (€ 28,411) Favourable step	€ 81,951 Profit after taxes 2025: € 81,951 ▲ 5% vs 2024 (€ 77,875) Favourable step	▲ 5%
Equity	€ 161,214 Equity 2022: € 161,214 First fiscal year in the series	€ 188,825 Equity 2023: € 188,825 ▲ 17% vs 2022 (€ 161,214) Favourable step	€ 265,867 Equity 2024: € 265,867 ▲ 41% vs 2023 (€ 188,825) Favourable step	€ 165,075 Equity 2025: € 165,075 ▼ 38% vs 2024 (€ 265,867) Unfavourable step	▼ 38%
Total debts	€ 63,344 Total debts 2022: € 63,344 First fiscal year in the series	€ 20,304 Total debts 2023: € 20,304 ▼ 68% vs 2022 (€ 63,344) Favourable step	€ 17,328 Total debts 2024: € 17,328 ▼ 15% vs 2023 (€ 20,304) Favourable step	€ 21,012 Total debts 2025: € 21,012 ▲ 21% vs 2024 (€ 17,328) Unfavourable step	▲ 21%
Cash	€ 219,525 Cash 2022: € 219,525 First fiscal year in the series	€ 205,508 Cash 2023: € 205,508 ▼ 6% vs 2022 (€ 219,525) Unfavourable step	€ 280,547 Cash 2024: € 280,547 ▲ 37% vs 2023 (€ 205,508) Favourable step	€ 183,301 Cash 2025: € 183,301 ▼ 35% vs 2024 (€ 280,547) Unfavourable step	▼ 35%
Retained profit	€ 159,214 Retained profit 2022: € 159,214 First fiscal year in the series	€ 186,825 Retained profit 2023: € 186,825 ▲ 17% vs 2022 (€ 159,214) Favourable step	€ 263,867 Retained profit 2024: € 263,867 ▲ 41% vs 2023 (€ 186,825) Favourable step	€ 163,075 Retained profit 2025: € 163,075 ▼ 38% vs 2024 (€ 263,867) Unfavourable step	▼ 38%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 800 Dividend 2023: € 800 Unchanged (€ 0) Unchanged	€ 833 Dividend 2024: € 833 ▲ 4% vs 2023 (€ 800) Unchanged	€ 182,743 Dividend 2025: € 182,743 ▲ € 181,910 vs 2024 (€ 833) Unchanged	▲ € 181,910
Bank debt	€ 198 Bank debt 2022: € 198 First fiscal year in the series	€ 232 Bank debt 2023: € 232 ▲ 17% vs 2022 (€ 198) Unfavourable step	€ 55 Bank debt 2024: € 55 ▼ 76% vs 2023 (€ 232) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 55) Favourable step	▼ 100%
Balance sheet total	€ 224,558 Balance sheet total 2022: € 224,558 First fiscal year in the series	€ 209,129 Balance sheet total 2023: € 209,129 ▼ 7% vs 2022 (€ 224,558) Unchanged	€ 283,195 Balance sheet total 2024: € 283,195 ▲ 35% vs 2023 (€ 209,129) Unchanged	€ 186,087 Balance sheet total 2025: € 186,087 ▼ 34% vs 2024 (€ 283,195) Unchanged	▼ 34%

Key figures of DR. KAAT GULDOLF - NEUROLOGIE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to DR. KAAT GULDOLF - NEUROLOGIE?

What happened at DR. KAAT GULDOLF - NEUROLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jan 5, 2026 New annual accounts for financial year 2025: profit of € 81,951 (▲ 5% vs 2024). Source: NBB ↗
Oct 1, 2020 New establishment in Antwerpen. KBO
Oct 1, 2020 Start of the company according to the CBE. KBO

In short

From € 159,214 profit in 2022 to € 81,951 profit in 2025.

Paid € 111,020 in corporate taxes since 2022.

Best year ever: 2022, with € 159,214 profit.

Paid out € 184,376 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. KAAT GULDOLF - NEUROLOGIE? We notify you, reason included.

Follow DR. KAAT GULDOLF - NEUROLOGIE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Kaat Guldolf

DR. KAAT GULDOLF - NEUROLOGIE

Behind DR. KAAT GULDOLF - NEUROLOGIE is Kaat Guldolf.

See the full network in the app

Directors

According to the 2025 annual accounts

Kaat Guldolf

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Kemelstraat(STE) 30A

9190 Stekene

2.308.137.665

Lindendreef 1

2020 Antwerpen

Active since 1 October 2020

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0755.535.077
VAT number: BE 0755.535.077
Registered office: Kemelstraat(STE) 30A, 9190 Stekene
Names & denominations: DR. KAAT GULDOLF - NEUROLOGIE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 1 October 2020
Peppol: Active · Active since 5 Jan 2026
Contact: [email protected] 0496053277
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗